文献速递免疫规划卫生政策与健康促进

设计基于证据的贝叶斯网络以估计阿斯利康COVID-19疫苗的风险与获益

Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine.
PubMed 文献 · Vaccine · 2022-04-08

研究开发了一个贝叶斯网络,整合阿斯利康COVID-19疫苗相关血栓形成伴血小板减少综合征(TTS)风险与获益的证据,模型参数来自多项实证研究、政府报告和专家咨询组,专家判断用于解读证据并确定模型结构、变量和数据使用。模型可作为决策支持工具,基于年龄、性别、病毒变异株和社区传播率生成情景,输出包括接种后死于TTS的风险以及不同情景下死于COVID-19或COVID-19相关非典型严重血栓的风险;模型聚焦澳大利亚,但可通过本地数据重新参数化以适应国际环境,并可扩展至其他疫苗、加强针、合并症和长期COVID等结局。

要点

  • 贝叶斯网络整合了阿斯利康COVID-19疫苗的TTS风险与获益证据,参数来自实证研究、政府报告和专家咨询组。
  • 模型可基于年龄、性别、病毒变异株和社区传播率生成情景,供个体、临床医生和研究人员评估不同健康结局的概率。
  • 模型聚焦澳大利亚,但可通过本地数据重新参数化以适配国际环境,并可扩展至其他疫苗、加强针、合并症和长期COVID等结局。

核心结论

  • 研究开发了一个贝叶斯网络,用于整合和有效传达阿斯利康COVID-19疫苗风险与获益的证据,可作为决策支持工具生成基于年龄、性别、病毒变异株和社区传播率的情景。

研究设计与样本

  • 研究设计为贝叶斯网络模型开发,参数化数据来自多项实证研究、政府报告和专家咨询组,专家判断用于解读证据并确定模型结构、相关变量、纳入数据及其使用方式。

主要发现

  • 模型输出包括接种阿斯利康COVID-19疫苗后死于TTS的风险,以及不同情景下死于COVID-19或COVID-19相关非典型严重血栓的风险。
  • 模型聚焦澳大利亚,但可通过本地数据重新参数化以适应国际环境。
  • 模型可扩展至其他COVID-19疫苗、加强针、合并症和其他健康结局(如长期COVID)。

临床怎么用

  • 模型可作为决策支持工具,供个体、临床医生和研究人员基于年龄、性别、病毒变异株和社区传播率评估不同健康结局的概率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Uncertainty surrounding the risk of developing and dying from Thrombosis and Thrombocytopenia Syndrome (TTS) associated with the AstraZeneca (AZ) COVID-19 vaccine may contribute to vaccine hesitancy. A model is urgently needed to combine and effectively communicate evidence on the risks versus benefits of the AZ vaccine. We developed a Bayesian network to consolidate evidence on risks and benefits of the AZ vaccine, and parameterised the model using data from a range of empirical studies, government reports, and expert advisory groups. Expert judgement was used to interpret the available evidence and determine the model structure, relevant variables, data for inclusion, and how these data were used to inform the model. The model can be used as a decision-support tool to generate scenarios based on age, sex, virus variant and community transmission rates, making it useful for individuals, clinicians, and researchers to assess the chances of different health outcomes. Model outputs include the risk of dying from TTS following the AZ COVID-19 vaccine, the risk of dying from COVID-19 or COVID-19-associated atypical severe blood clots under different scenarios. Although the model is focused on Australia, it can be adapted to international settings by re-parameterising it with local data. This paper provides detailed description of the model-building methodology, which can be used to expand the scope of the model to include other COVID-19 vaccines, booster doses, comorbidities and other health outcomes (e.g., long COVID) to ensure the model remains relevant in the face of constantly changing discussion on risks versus benefits of COVID-19 vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mayfield HJ, Lau CL, Sinclair JE, et al. Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine. Vaccine. 2022. PMID: 35450781. doi:10.1016/j.vaccine.2022.04.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。